In cisplatin-resistant gastric cancer, elevated ATF3 expression cooperates with erastin to inhibit the Keap1-Nrf2-xCT pathway, thereby promoting ferroptosis in cancer cells and reversing cisplatin resistance (Fu et al., 2021). This evidence concerns the gene ATF3 and gastric cancer.